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filgrastim, follitropin-alfa, infliximab, in-
sulin glargine, rituximab, somatropin, and 
teriparatide) with indications ranging from 
supportive therapies to treatment of chronic 
diseases [1].
By 2020, biological drugs will account for 
about 28% of the entire pharmaceutical mar-
ket and biosimilar drugs have the potential 
to represent an important part of this global 
market. It is indeed estimated that, by 2020 
the patent expirations of biological/biotech-
nological drugs will give biosimilars the 
chance to enter the markets for key biolog-
ics, currently accounting for over € 40 bln in 
sales [3].
IntroductIon
The European Medicines Agency (EMA) 
defines a biosimilar as «a biological medi-
cine that is similar to another biological 
medicine that has already been authorized 
for use» [1]. Followed by recent expiry of 
a number of patents of biologic drugs, the 
presence of biosimilars in the European 
market has considerably grown, increasing 
the therapeutic alternatives for many severe 
diseases [2]. Indeed, since the authorization 
of the first biosimilar drug (somatropin) in 
April 2006, EMA authorized 29 biosimilar 
products of 11 different molecules (adalim-
umab, enoxaparin, epoetin-alfa, etanercept, 
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AbstrAct
INTRODUCTION: Biosimilar products play an important role in improving the access to biological medicines for an in-
creased number of patients and enhancing the financial sustainability of the health systems.
AIM: To assess the cost saving potential associated with the introduction of two biosimilars (Benepali® and Flixabi®) vs. 
their respective reference biological products on the European and Italian markets.
METHODS: A budget impact model was developed to estimate the cost saving of the hypothetical introduction of Bene-
pali® and Flixabi® vs. Enbrel® and Remicade®, respectively, in three European countries. The analysis was conducted from 
the payer perspective, over a 3-year period. In addition, the same model was used to assess the impact of Benepali® vs. 
Enbrel® in three Italian regions over a 2-year period. The model compares the costs associated with the current treatment 
patterns, used to manage patients with all the conditions which Benepali® and Flixabi® are authorized for, with that of a hy-
pothetical treatment pattern in which biosimilar products have been introduced. Only direct costs associated with the drug 
acquisition were considered. The model was constructed using published country- or region-specific data, where available. 
Annual drug acquisition costs were calculated using the dosing information from SPCs and country-/region-specific price 
lists.
RESULTS: The introduction of Benepali® and Flixabi® in the biologic therapeutic setting of three European countries 
resulted in substantial cost savings across the entire scenario, with different penetration over a 3-year period. Similarly, 
over a 2-year horizon, the introduction of Benepali® in the biologic therapeutic setting of three Italian regions resulted in 
significant cost savings. In all cases, the greater savings were observed in the scenario where the biosimilars’ penetration 
was higher.
CONCLUSIONS: The introduction of Benepali® and Flixabi® has a substantial cost saving potential for the Italian and 
European health systems, and the budget impact is sensitive to the uptake rates of the biosimilars market. 
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ties, specifying that the choice to prescribe 
the biosimilar instead of the originator should 
be taken by qualified healthcare professionals 
[1].
Due to this heterogeneity also biosimilar up-
take is very different across Europe and an 
economic model for biosimilars doesn’t ex-
ist [8]. Two reports performed by Bocquet et 
al. [9,10] analyzed the markets of granulo-
cyte-colony stimulating factor (G-CSF) and 
erythropoietin (EPO) in 5 European countries 
(France, Germany, Italy, Spain and UK) in 
order to identify factors that affecting bio-
similars uptake. The analysis on G-CSF [9] 
shows that the market of biosimilar filgras-
tim was globally low in the first 5 years. The 
key drivers for biosimilar penetration seem to 
be market structure and type of distribution 
channel, indeed Germany and France, which 
have the largest markets with a predominant 
retail distribution, have the lower uptake, 
while Spain and UK, which have the smaller 
markets with a predominant hospital distri-
bution, have the highest uptake. The price 
difference between biosimilar and originator 
has a marginal role. In the study on biosimilar 
EPO [10] didn’t find a link between biosimi-
lar uptake, market size, distribution channel, 
and price discount.
In Italy, the Italian Medicines Agency (AIFA) 
states that even if biosimilars are therapeutic 
options with the same risk-benefit ratio as the 
originators, biologics and biosimilars can’t 
be considered generic drugs and the decision 
to switch from one biological medicine to 
another must be left to the judgment of the 
treating physician [5]. Given the absence of 
national guidelines, some Italian regions is-
sued directives and decrees aiming to encour-
age the use of biosimilars but giving different 
recommendation for their use. This situation 
lead to a heterogeneous scenario in terms 
of utilization and penetration of biosimilar 
drugs.
The aim of this economic analysis is to assess 
the potential savings associated with the in-
troduction of two biosimilars (Benepali® and 
Flixabi®), vs. their respective reference bio-
logical products in the European market(s) 
and in particular in a number of Italian mar-
kets, taking into consideration different pen-
etration and pricing scenarios.
Benepali®
Benepali® (SB4) is the first biosimilar to ref-
erence etanercept, a protein produced by re-
combinant DNA technology and designed to 
block the activity of the tumor necrosis factor 
(TNF). Following a comprehensive and step-
wise assessment of the totality of evidence 
required by the EMA for biosimilar develop-
Biological/biotechnological drugs have ad-
vantages over chemically processed medi-
cines including highly specific and complex 
functions and fewer off-target effects thus 
they offer new treatment options for treat-
ment and prevention of some serious illness 
[4]. However, they are associated with high 
research and development costs, which re-
spectively leads to their high market value. 
As a result, use of these drugs leads to in-
creased treatment costs and a growing bur-
den on health care systems. In this scenario, 
biosimilar products could play an important 
role, not only by improving the access to bio-
logical medicines for an increased number 
of patients, but also enhancing the financial 
sustainability of the health care systems. The 
entry of biosimilars into the market could im-
prove the access to biological drugs in two 
ways: first, biosimilars generate competi-
tion with the originators, with a consequent 
reduction in the prices; second, the savings 
associated with the use of biosimilars can 
be reallocated to improve the access to other 
drugs [5]. It is estimated that the daily treat-
ment cost of the originators, which are go-
ing to lose their patents between 2016 and 
2020, will decrease by about 30% due to the 
competition with the new biosimilars. This 
reduction could lead to a cumulative saving 
of about € 15 bln for the European health 
systems over the next five years [3], as also 
shown in a study that was presented at the 
ISPOR Annual International Meeting in May 
2017 [6]. The latter has shown that the intro-
duction of biosimilars of the three anti-TNFs 
(infliximab, etanercept, and adalimumab) in 
Europe resulted in a total saving of $ 11.44 
bln between 2015 and 2020.
Biosimilars are authorized by EMA through 
centralized procedure, therefore the authori-
zation is effective in every European Member 
State. However, there are significant differ-
ences among EU countries in terms of market 
penetration and pricing and reimbursement 
policies, as showed by a recent survey con-
ducted in 32 countries (the 28 EU Member 
States plus Norway, Serbia, Switzerland and 
Turkey) [7]. According to the answers re-
ceived the survey shows that a large major-
ity of the countries have specific policies in 
place for the entry of biologicals and biosimi-
lars in the market, but there is heterogeneity 
in design and implementation between the 
different countries [7].
Biosimilar interchangeability is another as-
pect that is not uniform across Europe. While 
the US Food and Drugs Administration 
(FDA) defines the interchangeable status of 
a biosimilar at the time of its authorization, 
EMA leaves the decision to the local authori-
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ment of rheumatoid arthritis, Crohn’s disease, 
ulcerative colitis, ankylosing spondylitis, 
psoriatic arthritis, and psoriasis [12]. Flixabi® 
is the second biosimilar to infliximab receiv-
ing marketing authorization in Europe after 
CT-P13 (marketed as Remsima® by Celltrion 
Healthcare Hungary Kft and as Inflectra® by 
Hospira UK Limited) which was approved in 
2013 for the full range of indications of the 
originator product [13,14].
Methods
A budget impact model was developed to es-
timate the cost saving of the hypothetical in-
troduction of Benepali® and Flixabi® vs. their 
respective reference biological products (En-
brel® and Remicade®, respectively) in three 
European countries (Benepali® in France, 
Italy, and Sweden; Flixabi® in France, Italy, 
and UK). A separate analysis estimated also 
availability of 
biologicals
are 
biosimilars 
undergoing 
hTa?
Pharmacy 
substitution
Tenders
are biological 
medicines 
included in 
the quotas?
are biological 
medicines 
parts of IrP 
mechanism?
France Reimbursement 
+ tenders
Yes No Biologicals are part of multiple-
win tenders organized at 
hospital level. Tender cover 
only ATC5 level and affect both 
naïve and in-treatment patients. 
Tender may lead to changes of 
treatment for already treated 
patients for other than clinical 
reasons and physician can opt 
out for individual patients.
No No
Italy Tenders Yes No Biologicals are part of single-
win tenders organized at 
regional level. Tender cover only 
ATC5 level and affect only naïve 
patients. Physician can opt out 
for individual patients.
Biologicals 
are part of 
just indicative 
quotas.
No
Sweden Reimbursement 
+ tenders
Yes No Biologicals are part of single-
win tenders organized at 
regional level. Tender cover 
only ATC5 level and affect both 
naïve and in-treatment patients. 
Tender may lead to changes of 
treatment for already treated 
patients for other than clinical 
reasons and physician can opt 
out for individual patients.
No No
UK Reimbursement 
+ tenders
No No Biologicals are part of multiple-
win tenders organized at 
multiple levels. Tender cover 
both a whole therapeutic area 
and only ATC5 level and affect 
both naïve and in-treatment 
patients. Tender may lead 
to changes of treatment for 
already treated patients for 
other than clinical reasons 
and physician can opt out for 
individual patients.
No No
Table I. Pricing and reimbursement policies for biologicals in the four countries considered. Modified from [7]
ATC = Anatomical Therapeutic Chemical; IRP = Internal Reference Pricing
ment and approval, SB4 was approved by the 
European Commission (January 14th 2016) 
for the treatment of rheumatoid arthritis, pso-
riatic arthritis, axial spondyloarthritis (an-
kylosing spondylitis and non-radiographic 
spondyloarthritis), and plaque psoriasis. SB4 
is the first biosimilar to etanercept available 
in Europe as well as the first subcutaneous 
anti-tumor necrosis factor biosimilar [11].
Flixabi®
Flixabi® (SB2) is a biosimilar to reference 
infliximab, a monoclonal antibody produced 
by recombinant DNA technology that binds 
to soluble and transmembrane forms of TNF-
alpha and inhibits its functional activity. Fol-
lowing a comprehensive and stepwise assess-
ment of the totality of evidence required by 
the EMA for biosimilar development and ap-
proval, SB2 was approved by the European 
Commission (May 05th 2016) for the treat-
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tinuing the anti-TNF treatment or by ceasing 
to exist.
The model considers only the drug acquisi-
tion costs. Clinical outcomes are assumed to 
be identical in all patients, regardless of the 
anti-TNF treatment received. As such, the 
costs associated with the management of the 
latter are not included in the model. Finally, in 
line with third-party payers’ perspective, indi-
rect costs are not considered in the analysis.
The model was constructed using published 
country- or region-specific data, where avail-
able. Annual drug acquisition costs were cal-
culated using dosing information from the 
SPCs and country-/region-specific price lists.
Table I shows the pricing and reimbursement 
policies for biologicals adopted in the four 
countries considered.
Benepali®
The eligible population included incident and 
prevalent patients aged 18 years and older 
with all conditions for which Benepali® has 
the European authorization in adults, with 
no distinction between naïve and switching 
patients.
Assumptions for the budget impact 
analysis of 3 European countries
The model assessed the budget impact of the 
introduction of Benepali® in France, Italy, 
and Sweden over a three year-period. The 
current etanercept-treated population size has 
been estimated using data from Groupement 
pour l’èlaboration et la realization de statis-
tiques for France [16], IMS Health for Italy 
[15], and Reveal for Sweden [17]. Popula-
tion size was assumed to increase annually 
by 1.8% in France [16], 1% in Italy [15], and 
5.8% in Sweden [17]. Use of etanercept over 
the next three years was predicted by estimat-
ing the annual historical volume change over 
the past 2 years for each country [15-17] and 
applying that to the following 3 years. Table 
II shows three different hypothetical scenar-
ios of Benepali® penetration in the markets 
of the three countries These percentages were 
assumed in order to simulate a slow, moder-
ate, and rapid uptake.
Unitary drug costs were obtained from coun-
try specific price lists [18-20] and did not 
include possible undisclosed or commercial 
discounts (which are not disclosed in France 
and Italy) with the exception of the Swedish 
Benepali net price, which was obtained from 
the three party discount agreement (from 1 
April 2016 to 30 September 2016) [Data on 
file]. Prices for France and Italy were in Eu-
ros; prices for Sweden were converted from 
Swedish Krona (SEK) to Euros using the ex-
change rate on 2 June 2016 (€ 1 = 9.29 SEK) 
[21].
Benepali® market share (%)
Year 1 Year 2 Year 3
Scenario 1 – slow uptake 10 20 30
Scenario 2 – moderate uptake 15 30 45
Scenario 3 – rapid uptake 20 40 60
Table II. Different scenarios of Benepali® market share
the budget impact of Benepali in UK and the 
results are shown later in the article, while 
the impact of Flixabi® was not evaluated in 
Sweden because it is not yet available there. 
We chose these countries because at the time 
of the launch of Flixabi® and Benepali® they 
didn’t have a mechanism in place to support 
biosimilar adoption, so we aimed to present 
the potential saving deriving from the intro-
duction and the penetration of biosimilar in 
these markets. The analysis was conducted 
from the payer perspective, over a 3-year pe-
riod. In addition, the impact of Benepali® vs. 
Enbrel was assessed in three Italian regions 
(Campania, Sicily and Tuscany) with differ-
ent penetration of the biosimilar product over 
a 2-year period. We choose Campania, Sicily, 
and Tuscany because we wanted to evaluate 
the budget impact in regions that have simi-
lar populations but uptake of previous bio-
similars was different [15], i.e. one with high 
(Tuscany), one with medium (Campania) and 
one with low uptake (Sicily).
Model structure and input
The model compares the costs associated 
with the current treatment pattern used to 
manage patients with all conditions which 
Benepali® and Flixabi® are authorized for, 
with the costs associated with a hypothetical 
scenario in which biosimilar products have 
been introduced. Based on this comparison, 
the model provides estimates of the budget 
impact of an increased use of Benepali® and 
Flixabi® in the eligible patient population 
and the hypothetical additional number of 
patients who could be managed using the re-
vised treatment pattern within the same bud-
getary restrictions.
Current etanercept-treated population size 
has been derived from the country-/region-
specific sales data; use over time horizon was 
predicted by estimating the percentage in-
crease in the size of anti-TNF-treated popula-
tion over a two-year period and by applying 
such figure to the following years. Patients 
who enter the model remain on anti-TNF 
treatment throughout the model time horizon, 
thus, according to the model assumptions, the 
patient population does not decrease in size 
due to patients exiting the model by discon-
65Farmeconomia. Health economics and therapeutic pathways 2017; 18(1)
C. Negrini, E. Psachoulia
treatment cost of Benepali was used. This 
estimation was based on etanercept moving 
annual total sales data, assuming that each in-
dividual consumed one defined daily dose (7 
mg) per day. It was assumed that all patients 
were fully persistent and compliant.
Flixabi®
The eligible population included incident and 
prevalent patients aged 18 years and older 
with all conditions for which Flixabi® has 
the European authorization in adults, with 
no distinction between naïve and switching 
patients.
The model assessed the budget impact of 
the introduction of Flixabi® in France, Italy, 
and United Kingdom (UK) vs. the inflix-
imab reference product (Remicade®) over 
a 3 year-period. The current Remicade®-
treated population size was estimated using 
data from Groupement pour l’èlaboration 
et la realization de statistiques for France 
[16], IMS Health for Italy and UK [15,22]. 
Based on what it was observed in the market 
[15,16,22], population size was assumed to 
remain constant during the 3 years, and pa-
tients already on the first two approved bio-
similars (Remsima® and Inflectra®) were as-
sumed to remain on these biosimilars.
Two model scenarios with different Flixabi® 
penetration (percentages were assumed in or-
der to simulate a slow, moderate, and rapid 
uptake) in the three countries were developed 
(Table IV). Unitary drug costs were obtained 
from country-specific price lists [18,23,24] 
and did not include possible undisclosed or 
commercial discounts (which are not dis-
closed). Prices for France and Italy were in 
Euros; prices for UK were converted from 
British Pound (GBP) to Euros using the ex-
Uptake Discount
Flixabi® market share (%) Flixabi® discount (%)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Scenario 1 Slow Minimum 10 20 30 40 28 30
Scenario 2 Slow Maximum 10 20 30 50 45 50
Scenario 3 Rapid Minimum 20 40 60 40 28 30
Scenario 4 Rapid Maximum 20 40 60 50 45 50
Table IV. Different scenarios of Flixabi® market share and discount
The following assumptions were applied to 
the model scenarios:
 - Based on the actual differences between 
the visible prices Benepali® discounts vs. 
the etanercept reference product, Enbrel®, 
was 17.6% in France, 31.7% in Italy, and 
34.8% in Sweden;
 - Based on what have been seen with previ-
ous biosimilar a price erosion was 10% 
per year in all three countries for both 
etanercept drugs
Assumptions for the budget impact 
analysis of 3 Italian regions
The model assessed the budget impact of the 
introduction of Benepali® in three Italian re-
gions (Campania, Sicily and Tuscany), with 
different scenario in terms of utilization and 
penetration of biosimilar drugs due to dif-
ferent mechanisms to support the biosimilar 
adoption, over a 2-year period. The current 
etanercept-treated population size was esti-
mated through IMS Health data [15]. Popula-
tion size was assumed to increase annually 
by 1% in all three regions.
The model scenarios with the adoption rates 
of Benepali® vs. Enbrel® in each region 
were developed assuming that the Benepali® 
market share at year 1 was the same as that 
achieved by the previous biosimilars already 
in the market from 2015 (Inflectra®/Rem-
sima®) (7% in Campania, 14% in Sicily, and 
52% in Tuscany [22]). A logarithmic function 
was then used to model the uptake in the en-
tire year 2, based on the available 3-month 
sales data of year 3 of infliximab biosimilars 
in each region [22]. Table III shows the sce-
narios of Benepali® penetration in the three 
Italian regions.
Unitary drugs costs were obtained from Cod-
ifa and did not include possible undisclosed 
or commercial discounts [18]; Benepali® dis-
counts were assumed to be the same across 
regions and equal to 31.7% vs. Enbrel (ac-
tual differences between the visible prices) 
[18]. Both etanercept drugs were subject to 
a price erosion of 10% per year in all three 
regions.
For the estimation of the additional patient-
years of etanercept treatment, the annual 
Benepali® market share (%)
Year 1 Year 2
Campania 7 18
Sicily 14 27
Tuscany 52 74
Table III. Regional scenario of Benepali® market share
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change rate on 2 June 2016 (€ 1 = 1.29 GBP) 
[21]. Two price scenario with two discount 
prices for Flixabi® vs. the Remicade® price 
(minimum and maximum discount given by 
the other two infliximab biosimilars in each 
country) were developed (Table IV). Since 
prices already decreased due to the first bio-
similars entry, we assumed a smaller discount 
due to the Flixabi® entry, therefore in this 
analysis both originator and biosimilar were 
subject to a price erosion of 5% per year in all 
three countries.
results
Benepali®
The estimated numbers of patients who 
would receive the etanercept treatment (both 
originator and biosimilar) in the first year in 
France, Italy and Sweden; and in the three 
Italian regions are presented in Table V. The 
introduction of Benepali® in the biologic 
treatment setting of three European countries 
resulted in substantial cost savings across the 
entire scenario, with different biosimilar pen-
etration over 3 years (Figure 1). The greater 
savings were observed in scenario 3, where 
Benepali® penetration was higher (France = 
€ 51.5 mln; Italy = € 63.0 mln; Sweden = € 
30.7 mln).
Similarly, over the 2-year time horizon, the 
introduction of Benepali® in the biologic 
treatment setting of three Italian regions re-
sulted in a substantial cost saving (Figure 2). 
Similarly to the above scenario in the three 
European countries, the greater savings were 
in the region with the higher penetration of 
Benepali® (Tuscany = € 5.9 mln vs. Campa-
nia = € 1.3 mln, and Sicily = € 1.7 mln).
Expressing these cost savings in terms of 
additional patients who could receive treat-
ment with Benepali® under the same bud-
getary restrictions, the European economic 
analysis estimated that, over the next 3 years, 
the additional patients who could be treated 
with Benepali® were 3,850-7,676 in France, 
4,420-8,840 in Italy, and 2,050-4,080 in Swe-
den. In the analysis of the Italian regions, the 
potential capacity to treat additional patients 
under the revised treatment pattern over the 
next 2 years was 175 in Campania, 227 in 
Sicily, and 761 in Tuscany.
Etanercept-treated population – year 1 (n.)
European comparison
France 29,371
Italy 15,659
Sweden 5,919
Italian comparison
Campania 1,501
Sicily 1,180
Tuscany 1,293
Table V. Estimated numbers of patients treated with etanercept (both originator 
and biosimilar) in the first year
Figure 1. Cost savings following the introduction of Benepali® in France, Italy and Sweden in years 1, 2 and 3 and cumulative Figure 2. Cost savings following the introduction of Benepali® in the three Italian regions
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Flixabi®
The estimated number of patients who would 
receive the infliximab treatment (both origi-
nator and biosimilar) in the first year was 
32,101 in France, 9,290 in Italy, and 18,617 
in the UK.
The introduction of Flixabi® in the biologic 
treatment setting of three European countries 
resulted in substantial cost savings across 
the entire scenario, with different biosimilar 
penetration and different pricing discount, as 
reported in Figure 3.
Expressing these cost savings in terms of ad-
ditional patients who could receive treatment 
with Flixabi® under the same budgetary re-
strictions over the next 3 years, the introduc-
tion of the biosimilar was predicted to allow 
for savings equivalent to the following addi-
tional patient-years of infliximab treatment: 
12,841-38,521 in France, 2,013-9,121 in Ita-
ly, and 4,788-22,341 in the UK.
dIscussIon And conclusIons
The recent several patent expirations of bio-
logical drugs led to the development of bio-
similar products. Those biosimilar products 
represent an important segment of the global 
pharmaceutical market. Competing with their 
originators in a wide range of therapeutic 
areas, biosimilars provide to stakeholders – 
payers, physicians and patients – a greater 
therapeutic choice. The entry of biosimi-
lars into the market has led to reduction of 
prices of the biological originator products, 
as shown by a study in which the introduc-
tion of three biosimilars, i.e. human growth 
hormone, erythropoietin, and granulocyte 
colony-stimulating factor, in the Italian mar-
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the associated potential savings. The analysis 
was based on the sales data of three biologi-
cal classes between 2007 and 2010 in eight 
European countries: France, Germany, Italy, 
Spain, UK, Sweden, Poland and Romania 
[26]. The model assumed the development 
of market shares, the average reimbursement 
prices and the time until the entry into the 
market of the biosimilar. The results high-
lighted that the potential savings associated 
with the introduction of biosimilars would be 
ket resulted in a price reduction of the origi-
nators equal to 9, 12, and 25%, respectively, 
between 2006 and 2013 [25].
The savings associated with the use of bio-
similars are also influenced by their avail-
ability after the patent expiry of the reference 
biological drug. One study, published in the 
Generic and Biosimilar Initiative Journal, 
developed a model which simulated different 
scenarios of the replacement of an origina-
tor with its biosimilar in order to evaluate 
Figure 3. Cost savings following the introduction of Flixabi® in France, Italy and UK
69Farmeconomia. Health economics and therapeutic pathways 2017; 18(1)
C. Negrini, E. Psachoulia
P13 across the five countries. Brodszky et al. 
[30] assessed the estimated budget impact of 
the introduction of CT-P13 in the treatment 
of rheumatoid arthritis over a 3-year period 
in six Eastern European countries and assum-
ing a 25% discount over the originator price. 
The results showed estimated saving equal 
to € 15.3 mln when only naïve patients were 
considered, while including also patients that 
switch from reference drug estimated saving 
reached € 20.8 mln. These savings could al-
low to treat 1,205 and 1,790 additional pa-
tients with rheumatoid arthritis, respectively.
In conclusion, the introduction of Benepali® 
and Flixabi® has a substantial cost saving 
potential for the Italian and European health 
systems, and the budget impact is sensitive 
to the uptake rates of the biosimilars market 
and the discounts compared to the origina-
tors. These savings could be used to treat ad-
ditional patients within the same therapeutic 
area, to fund the research on novel therapies 
for other disease areas, and/or potentially 
to finance other hospital or medical depart-
ment needs, as highlighted by the results of 
our budget impact of Benepali® applied to 
the UK scenario [31]. In this case, Benepali® 
discounts vs. Enbrel were 8.3% and the mod-
erate (market share = 15%, 30%, and 45% at 
year 1, 2, and 3, respectively) and rapid up-
take of Benepali® (market share = 20%, 40%, 
and 60% at year 1, 2, and 3, respectively) over 
3 years resulted in a saving of £ 14.2 mln and 
£ 18.9 mln, respectively. These could in turn 
generate further savings, equivalent to 1,781 
to 2,374 more patient-years and are equiva-
lent to the salaries of 468-623 more nurses 
for NHS England as reported by the Royal 
College of Nursing (NHS pay scales 2016-
17). In the light of this evidence, and from a 
resource-saving perspective, a collaborative 
agreement between payers and prescribers 
for a more flexible approach to the replace-
ment of reference biological products with 
biosimilars can support a more rapid adop-
tion of biosimilars generating savings while 
achieving better outcomes for patients. Few 
analyses have suggested some policies and 
approaches to establish and maintain a sus-
tainable biosimilar market [32]. Mestre-Fer-
randiz et al. have highlighted that, even if it is 
difficult to generalize across countries in Eu-
rope, there are five key elements to take into 
account to achieve sustainability and savings 
from the use of biosimilars:1) substitutability 
rules which allow the substitution at pharma-
cy level, 2) direct price intervention to push 
down originator prices, 3) tendering proce-
dures to facilitate competition and price re-
duction, 4) incentives for stake holders to use 
lower-cost products, and 5) market support 
between € 11.8 bln and € 33.4 bln, equal to 
5.2-14.6% of the total pharmaceutical expen-
diture, and that an immediate availability is 
associated with greater savings [26].
These results are consistent with our findings 
which showed that the introduction of Be-
nepali® and Flixabi® have a substantial cost-
saving potential for European health care 
systems. In both cases the budget impact was 
sensitive to biosimilar market uptake rate and 
the greater savings were observed where the 
penetration was higher. Similarly, in our Ital-
ian analysis, in Tuscany – where a mecha-
nism to support the biosimilar adoption is in 
place – the saving potential was greater than 
in the other two regions, where the uptake 
was slower, confirming that a faster avail-
ability maximizes the potential savings. In-
deed, it was estimated that if the adoption of 
Benepali® in Campania and Sicily were more 
rapid and the product reached the market 
share modeled for Tuscany, the total savings 
would be equal to € 6.8 mln in Campania and 
€ 5.3 mln in Sicily, which are respectively, € 
5.5 mln and € 3.6 mln greater than savings in 
the current analysis.
A further confirmation comes from the re-
sults of our budget impact model applied in 
an Italian rheumatologic center, in order to 
assess the economic impact of the introduc-
tion of Benepali® [27]. The analysis, present-
ed to the ISPOR European Congress 2016, 
showed a greater saving when 66.1% of the 
patients treated with etanercept receive Bene-
pali® at year 3 (€ 1.9 mln) vs. the slow uptake 
scenario where 52.2% of former etanercept 
patients receive Benepali® at year 3 (€ 1.6 
mln). Finally, even when applied to the Span-
ish setting (assuming a 10% discount of Be-
nepali® vs. Enbrel), this budget impact model 
showed that a more rapid uptake of Benepali® 
(market share = 20%, 40%, and 60% at year 
1, 2, and 3, respectively) resulted in a greater 
saving (€ 24.5 mln over 3 years) vs. a slower 
adoption rate (market share = 10%, 20%, and 
30% at year 1, 2, and 3, respectively, saving 
over 3 years: € 12.3 mln) [28].
Similar results were achieved by CT-P13 (the 
first biosimilar to infliximab) in two economic 
models built by Jha et al. [29] and Brodszky 
et al. [30]. The budget impact performed by 
Jha et al. [29], which considered both switch 
and naïve patients, showed that, during the 
first year after launch in Germany, UK, Italy, 
the Netherlands, and Belgium, CT-P13 was 
associated with a potential savings equal to 
€ 25.789, € 51.578, and € 77.367 in the three 
discount scenarios considered (10, 20 and 
30%, respectively) and for all the indications 
approved. Furthermore, 1,960, 4,410, 7,561 
additional patients could be treated with CT-
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plement policies that maintain and encourage 
competition; and 4) encourage a rational de-
cision making in which pricing, procurement, 
positioning and utilization decision-making 
processes are transparent and not delay time 
to pricing, reimbursement or market access 
of biosimilars.
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